# Nutex Health Inc.: Form 10-Q for the period ended Sep 30, 2017

- Company: [Nutex Health Inc.](/companies/nutx.md) (CIK 1479681)
- Form: 10-Q
- Filed: 2017-11-20
- Accepted by EDGAR: Nov 20, 2017, 14:22 ET
- Period: 2017-09-30
- Accession: 0001607062-17-000400
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1479681/000160706217000400/igmb093017form10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1479681/000160706217000400/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2017-07-01 to 2017-09-30 | $8.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2017-01-01 to 2017-09-30 | $22.6k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2017-07-01 to 2017-09-30 | $11.1k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2017-01-01 to 2017-09-30 | $5.4k | us-gaap:GrossProfit |
| Operating income | 3 months, 2017-07-01 to 2017-09-30 | −$711.9k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2017-01-01 to 2017-09-30 | −$2.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-07-01 to 2017-09-30 | $16.7k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2017-01-01 to 2017-09-30 | $30.3k | us-gaap:InterestExpense |
| Net income | 3 months, 2017-07-01 to 2017-09-30 | $6.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2017-01-01 to 2017-09-30 | $4.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-07-01 to 2017-09-30 | $0.06 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2017-01-01 to 2017-09-30 | $0.06 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2017-01-01 to 2017-09-30 | −$523.5k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2017-09-30 | $15.5k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-09-30 | $87.7k | us-gaap:AssetsCurrent |
| Total assets | at 2017-09-30 | $6.6m | us-gaap:Assets |
| Total liabilities | at 2017-09-30 | $734.0k | us-gaap:Liabilities |
| Shareholders' equity | at 2017-09-30 | $5.8m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 16,550 characters.

### FORWARD LOOKING STATEMENTS

This Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included or incorporated by reference in this Form 10-Q which address activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future capital expenditures (including the amount and nature thereof), finding suitable merger or acquisition candidates, expansion and growth of the Company’s business and operations, and other such matters are forward-looking statements. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments as well as other factors it believes are appropriate in the circumstances.

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Factors that could adversely affect actual results and performance include, among others, potential fluctuations in quarterly operating results and expenses, government regulation, technology change and competition. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements.

### INTRODUCTION

iGambit is a company focused on the medical technology markets. Our primary focus is the expansion of our newly acquired medical technology business HealthDatix Inc.

HealthDatix is an end to end Software-as-a-Service solution that manages, reports, and analyzes critical data, enabling healthcare organizations to deliver positive patient outcomes. HealthDatix provides an opportunity for physicians to identify patients eligible for both “Annual Wellness Visits” (AWV) as well as “Chronic Care Management” both of which are reimbursed by Medicare.

Our WellDatix solution offers a fully-hosted cloud service for healthcare providers to conduct the Medicare Annual Wellness Visit (AWV) program to their Medicare patients providing the patient with a 5-10 year Personalized Preventive Plan and physician reports that meet all Medicare audit requirements. The AWV is a program that allows a physician to identify those patients that have 2+ chronic conditions that require additional screening and management.

Additionally our CareDatix Chronic Care Management System, encompasses our FDA approved Electronic House Call system and Medicare covered platform, for continuous management of chronic care patients. The CareDatix platform can be tailored for individual care and health management of patients susceptible to chronic illness. The CareDatix platform is also designed to accumulate information from any TeleMedicine or wearable device.

***Assets.*** At September 30, 2017, we had $6,569,951 in total assets, compared to $510,835 at December 31, 2016. The increase in total assets was primarily due to the increase in intangible assets from the acquisition of certain assets from EncouterCare Solutions Inc. (“ECSL Acquisition) by our HealthDatix subsidiary.

***Liabilities.*** At September 30, 2017, our total liabilities were $734,038 compared to $6,380,260 at December 31, 2016. Our current liabilities at September 30, 2017 consisted of accounts payable and accrued expenses of $318,521, accrued interest on notes payable of $15,984, notes payable of $52,500, convertible debentures of $146,620, and derivative liability of $195,370 whereas our total liabilities at December 31, 2016 consisted of current liabilities including accounts payable and accrued expenses of $356,005, amounts due to related parties of $508, convertible debentures of $50,000 and liabilities from discontinued operations of $5,973,747. The decrease in total liabilities was due to the sale of our subsidiary WaLa. Inc. dba ArcMail Technologies Inc. (“ArcMail”).

***Stockholders’ Equity (Deficiency).*** Our Stockholders’ Equity was $5,835,913 at September 30, 2017 compared to Stockholders Deficiency of ($5,869,425) at December 31, 2016. This increase was primarily due to an increase in Common Stock and Additional paid-in capital from the ECSL acquisition, and a decrease in Accumulated Deficit due to the sale of ArcMail during the nine months ended September 30, 2017.

### Three Months Ended SEPTEMBER 30, 2017 as Compared to Three Months Ended SEPTEMBER 30, 2016

***Revenues and Net Income.*** We had $19,012 of revenue from our HealthDatix subsidiary and a net income of $6,325,014 during the three months ended September 30, 2017, compared to revenue of $0 and a net income of $216,666 for the three months ended September 30, 2016. The increase in revenue was due primarily to revenue generated by our HealthDatix subsidiary acquired in February 2017. In addition to HealthDatix’s operations, we had income from discontinued operations of $7,053,622 compared to income from discontinued operations of $293,036 for the three months ended September 30, 2017 and September 30, 2016, respectively.

***General and Administrative Expenses.*** General and Administrative Expenses increased to $723,000 for the three months ended September 30, 2017 from $75,699 for the three months ended September 30, 2016. For the three months ended September 30, 2017 our General and Administrative Expenses consisted of corporate administrative expenses of $25,942, amortization and depreciation expense of $325,799, legal and accounting fees of $19,180, employee benefits expenses (health and life insurance) of $14,427, marketing expenses of $18,662, payroll expenses of $86,757, exchange filing fees of $7,181, rent expense of $7,052, consulting fees expense of $186,000, commissions expense of $6,000, finders fess of $15,000 and research and development expense of $11,000. For the three months ended September 30, 2016 our General and Administrative Expenses consisted of corporate administrative expenses of $11,286, legal and accounting fees of $11,517, employee benefits (health and life insurance) expenses of $6,597, payroll expenses of $12,530, travel expenses of $9,289, marketing expense of $17,364, exchange and filing fees expense of $2,256, and rent expense of $4,860. The increases from the three months ended September 30, 2016 to the three months ended September 30, 2017 relate primarily due to: (i) an increase in payroll expense and employee benefits, (ii) an increase in marketing expenses; and (iii) an increase in general and administrative costs associated with the operation of our HealthDatix subsidiary as well as costs associated with the ECSL acquisition and ArcMail sale. Costs associated with our officers’ salaries and the operation of our HealthDatix subsidiary are expected to increase going forward, as we expand the business operations of HealthDatix which would likely increase our corporate administrative expenses.

***Other Income (Expense).*** We reported interest expense of $16,668 and $671 for the three months ended September 30, 2017 and 2016, respectively. A gain of $6,657,848 on the sale of ArcMail was reported for the three months ended September 30, 2017.

### NINE Months Ended SEPTEMBER 30, 2017 as Compared to NINE Months Ended SEPTEMBER 30, 2016

***Revenues and Net Income (Loss).*** We had $27,957 of revenue from our HealthDatix subsidiary and net income of $4,435,690 during the nine months ended September 30, 2017, compared to revenue of $0 and a net loss of $118,256, for the nine months ended September 30, 2016. The increase in revenue was due primarily to the revenue generated by our HealthDatix subsidiary acquired in February 2017. In addition to HealthDatix’s operations, we had income from discontinued operations of $6,589,713 compared to income from discontinued operations of $185,773, for the nine months ended September 30, 2017 and September 30, 2016, respectively.

***General and Administrative Expenses.*** General and Administrative Expenses increased to $2,129,083 for the nine months ended September 30, 2017 from $302,146 for the nine months ended September 30, 2016. For the nine months ended September 30, 2017 our General and Administrative Expenses consisted of corporate administrative expenses of $82,669, amortization and depreciation expenses of $664,556, board compensation expense of $134,856, legal and accounting fees of $129,981, employee benefits expenses (health and life insurance) of $40,670, marketing expense of $52,381, payroll expenses of $505,150, commissions fees expense of $70,475, consulting fees expense of $373,136, finders fees expense of $15,000, exchange filing fees of $18,515, rent expense of $19,694, and research and development expense of $22,000. For the nine months ended September 30, 2016 our General and Administrative Expenses consisted of corporate administrative expenses of $36,717, amortization and depreciation expenses of $355, board compensation expense of $6,000, legal and accounting fees of $52,842, employee benefits expenses (health and life insurance) of $17,786, marketing expense of $50,698, payroll expenses of $68,788, commissions and fees expense of $26,250, directors and officers insurance expense of $10,053, exchange filing fees of $10,834, rent expense of $14,520 and travel expense of $10,573. The increases from the nine months ended September 30, 2016 to the nine months ended September 30, 2017 relate primarily due to: (i) an increase in payroll expense and employee benefits, (ii) an increase in marketing expenses; and (iii) an increase in general and administrative costs associated with the operation of our HealthDatix subsidiary as well as costs associated with the ECSL acquisition and ArcMail sale. Costs associated with our officers’ salaries and the operation of our HealthDatix subsidiary are expected to increase going forward, as we expand the business operations of HealthDatix which would likely increase our corporate administrative expenses.

***Other Income (Expense).*** We reported interest expense of $30,333 and $1,883 for the nine months ended September 30, 2017 and 2016, respectively. A gain of $6,657,848 on the sale of ArcMail was reported for the nine months ended September 30, 2017.

### Liquidity and Capital Resources

### General

As reflected in the accompanying unaudited consolidated financial statements, at September 30, 2017, we had $15,489 of cash and stockholders’ equity of $5,835,913. At December 31, 2016, we had $10,522 of cash and stockholders’ deficiency of $(5,869,425).

Our primary capital requirements in 2017 are likely to arise from the expansion of our HealthDatix operations. It is not possible to quantify those costs at this point in time, in that they depend on HealthDatix’s business opportunities and the state of the overall economy. We anticipate raising capital in the private markets to cover any such costs, though there can be no guaranty we will be able to do so on terms we deem to be acceptable. We do not have any plans at this point in time to obtain a line of credit or other loan facility from a commercial bank.

While we believe in the viability of our strategy to improve HealthDatix’s sales volume, and in our ability to raise additional funds, there can be no assurances that we will be able to fully effectuate our business plan.

We believe we will continue to increase our cash position and liquidity for the foreseeable future. We believe we have enough capital to fund our present operations.

### Cash Flow Activity

Net cash used in operating activities was $523,545, for the nine months ended September 30, 2017, compared to $200,571 for the nine months ended September 30, 2016. Net cash used in continuing operating activities was $522,984 for the nine months ended September 30, 2017, compared to $78,679 for the nine months ended September 30, 2016. Our primary use of operating cash flows from continuing operating activities was from net income of $4,435,690 and $118,256 for the nine months ended September 30, 2017 and 2016, respectively. Additional contributing factors to the change were from depreciation expense of $830, amortization expense of $663,726, non-cash interest expense of $9,812, stock based compensation of $938,825, an increase in accounts receivable of $8,725, a decrease in prepaid expenses of $48,071, a decrease in accounts payable and accrued expenses of $37,484, and an increase in accrued interest on notes payable of $15,984. Net cash used in discontinued operations was $561 for the nine months ended September 30, 2017 and net cash used in discontinued operating activities was $121,892 for the nine months ended September 30, 2016. Cash provided by discontinued operations was primarily due to a decrease in accounts receivable from discontinued operations for the nine months ended September 30, 2017, and cash used in discontinued operations was primarily from net losses of $107,263 from the ArcMail subsidiary for the nine months ended September 30, 2016.

Net cash used in continuing investing activities was $31,023 for the nine months ended September 30, 2017 and $0 for the nine months ended September 30, 2016. For the nine months ended September 30, 2017 the primary use of cash flows in investing activities was pre-acquisition loans to subsidiaries and loans to our Arcmail subsidiary prior to deconsolidation. Net cash provided by discontinued investing activities was $0 for the nine months ended September 30, 2017 and $15,902 for the nine months ended September 30, 2016.

Net Cash provided by financing activities was $559,535 for the nine months ended September 30, 2017 compared to $77,714 for the nine months ended September 30, 2016. The cash flows provided by continuing financing activities for the nine months ended September 30, 2017 was primarily from $275,000 in proceeds from the sale of common stock and $288,000 in proceeds from issuance of convertible debentures. The cash flows provided by continuing financing activities for the nine months ended September 30, 2016 consisted of an increase in amounts due to related parties of $5,515. The cash flows provided by discontinued financing activities for the nine months ended September 30, 2017 was $0 compared to $72,199 in cash flows provided by discontinued financing activities for the nine months ended September 30, 2016.

### Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next twelve months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

## Controls and procedures

As filed, 1,915 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of September 30, 2017, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting

### Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Filed Nov 20, 2017.
Source: SEC EDGAR, the filing index for accession 0001607062-17-000400. Last ingested by Listed: Nov 14, 2026, 12:46 ET. No prices; not investment advice.
